PA500383: Cardiovascular therapeutics
[Page last updated: 03 August 2022]
Academic Year: | 2022/23 |
Owning Department/School: | Department of Pharmacy & Pharmacology |
Credits: | 15 CATS credits |
Notional Study Hours: | 150 |
Level: | FHEQ level 7 |
Period: |
|
Assessment Summary: | PF 100% |
Assessment Detail: |
|
Supplementary Assessment: |
|
Requisites: | In taking this module you cannot take PA500406 AND take PA500407 |
Learning Outcomes: | * Critically analyse and evaluate the pathophysiology of acute and chronic cardiovascular conditions, the pharmacology of key medicines, and apply these to support optimisation of therapeutic selection, administration and monitoring in these conditions * Use effective communication strategies to support patients (and carers, advocates, representatives) and healthcare professionals to make medicines optimisation decisions; taking into account patient views/beliefs/ICE (ideas, concerns, expectations) * Identify, critically evaluate and apply key evidence sources in order to effect medicines optimisation outcomes within these clinical conditions * Identify and employ effective patient activation strategies to support patients with these conditions * Design enhancements to medicines and health services, including effective use of health resources, patient facing services and clinical governance structures * Reflect on learning experiences, evaluate performance, and identify performance gaps within this clinical area to support ongoing development. |
Aims: | To update the underpinning knowledge of pharmacology, pathophysiology and medicines optimisation to support the clinical management of patients with acute and chronic cardiovascular conditions. |
Skills: | * Clinical skills * Study skills * Written communication * Working with others * Scientific and practical skills * Improving learning and performance * Information and communication technology * Problem solving. |
Content: | * Pathophysiology of key conditions including: - Ischaemic Heart Disease (IHD) - Angina - Acute Coronary Syndrome (ACS): Unstable Angina (UA) & non-ST segment elevation Myocardial Infarction (NON-ST-ACS) - ACS: STEMI (ST elevation myocardial infarction) - Secondary Prevention of IHD - Heart Failure - Cardiac Arrhythmias - Hypertension - Infective conditions * Pharmacology, administration and monitoring of medicines used in the treatment of these conditions * Drug-disease interactions specific to these conditions * Pharmacoeconomic consideration of medicines optimisation * Professional and ethical values * Communication, negotiating and agreeing healthcare decisions. |
Programme availability: |
PA500383 is Optional on the following programmes:Department of Pharmacy & Pharmacology
|
Notes:
|